Skip to main content
. 2014 Jan 21;4(1):e349. doi: 10.1038/tp.2013.123

Figure 1.

Figure 1

MeCP2 binding to RELN, GAD1 and GAD2 promoters and gene bodies and correlations with corresponding mRNA in the cerebella of CON and ASD. (a) MeCp2 binding to the promoter regions of RELN ((−220 to +70), (*P=0.03)) and GAD1 ((−55 to +121), (*P=0.04)) are increased in ASD vs CON, while GAD2 ((−1507 to +1310) (P=0.32)) is unchanged in ASD vs CON. (b) MeCP2 binding to gene body regions of RELN ((+562 to +763), (P=0.2)), GAD1 ((+656 to +856), (P=0.6)) and GAD2 ((+1293 to +1447), (P=0.9)) are unchanged in ASD vs CON. (c) Increased binding of MeCP2 to the RELN promoter was associated with reduced RELN mRNA (Pearson r2=−0.66, *P=0.04, n=10) in ASD. (d) Increased binding of MeCP2 to the GAD1 promoter shows a trend to statistical significance with decreased GAD1 mRNA expression (Pearson r2=−0.53; P=0.08, n=10) in ASD. ASD, autism spectrum disorder; CON, control; GAD1, glutamic acid decarboxylase 67; GAD2, glutamic acid decarboxylase 65; RELN, Reelin.